Loading…

Towards Light‐Activated Ruthenium–Arene (RAPTA‐Type) Prodrug Candidates

Cancer is currently one of the deadliest diseases worldwide. Based on the high incidence of this disease, the side effects associated with current chemotherapies and the appearance of drug resistance, considerable efforts have been directed towards the development of new anticancer drugs with new mo...

Full description

Saved in:
Bibliographic Details
Published in:Chembiochem : a European journal of chemical biology 2019-11, Vol.20 (22), p.2876-2882
Main Authors: Renfrew, Anna K., Karges, Johannes, Scopelliti, Rosario, Bobbink, Felix D., Nowak‐Sliwinska, Patrycja, Gasser, Gilles, Dyson, Paul J.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Cancer is currently one of the deadliest diseases worldwide. Based on the high incidence of this disease, the side effects associated with current chemotherapies and the appearance of drug resistance, considerable efforts have been directed towards the development of new anticancer drugs with new modes of action. Metal‐based compounds are particularly attractive candidates due to their metabolic mechanisms, which differ substantially from those of organic drugs. Of special interest in this context are organometallic ruthenium(II) complexes of the type [Ru(η6‐arene)(pta)Cl2] (arene: p‐cymene, toluene, benzene, etc.; pta: 1,3,5‐triaza‐7‐phosphaadamantane), which are abbreviated to RAPTA. Complementary to chemotherapy, photoactivated chemotherapy is a technique that has received increasing attention towards the development of treatment for numerous kinds of cancer. With this in mind, a photoactive RAPTA‐type complex bearing azide ligands has been designed. The diazide complex, [Ru(η6‐p‐cymene)pta‐(N3)2], is inert in water, but slowly releases the azide ligand upon exposure to light. Consequently, the in vitro cytotoxicity of the complex in the dark and upon light exposure at λ=450 nm in human cervical carcinoma (HeLa) and noncancerous retinal pigment epithelium (RPE‐1) cells was investigated. Although the cytotoxicity of the complex was found to be modest in the dark, an increase in toxicity upon light exposure was observed. Make a PACT: A diazide complex, [Ru(η6‐p‐cymene)pta(N3)2] (pta: 1,3,5‐triaza‐7‐phosphaadamantane), is inert in water, but slowly releases the azide ligand upon exposure to light. The in vitro cytotoxicity of the complex in the dark and upon light exposure in human cervical carcinoma and noncancerous retinal pigment epithelium cells is investigated.
ISSN:1439-4227
1439-7633
DOI:10.1002/cbic.201900236